Comparison of Dolutegravir+Lamivudine and Bictegravir/Emtricitabine/Tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice

Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With HIV-1: Results Through Week 144 From the Phase 3, Non-inferiority TANGO Randomized Trial

(2022) Olayemi Osiyemi et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial

(2022) Josep M Llibre et al.   CLINICAL INFECTIOUS DISEASES

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV

(2022) Javier Martínez-Sanz et al.   Frontiers in Immunology

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

(2021) Rickesh Patel et al.   Infectious Diseases and Therapy

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

(2020) Jean van Wyk et al.   CLINICAL INFECTIOUS DISEASES

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment

(2020) Ashima Pyngottu et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors

(2020) G Schuettfort et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation

(2018) April C Pettit et al.   Journal of the International AIDS Society

Comparison of different methods for causality assessment of adverse drug reactions

(2018) Sapan Kumar Behera et al.   International Journal of Clinical Pharmacy

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen

(2017) François Raffi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy

(2016) Jessica L. Castilho et al.   AIDS

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study

(2015) Cristina Mussini et al.   Lancet HIV

Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection

(2014) D. A. Osterholzer et al.   CLINICAL INFECTIOUS DISEASES

Course and Clinical Significance of CD8+T-Cell Counts in a Large Cohort of HIV-Infected Individuals

(2014) Marie Helleberg et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*

(2012) C Stephan et al.   HIV MEDICINE